Federal Officials Investigate Potential Link Between Diabetes Drug Januvia and Pancreatic CancerMay 31, 2013
Federal health officials are set to launch an investigation into a possible link between the type 2 diabetes drug Januvia (sitagliptin) and a risk of pancreatic cancer.
According to a New York Times report, the U.S. Food and Drug Administration (FDA) is acting on the research of a single person who said he found that lab rats taking Januvia had developed pancreatic cancer. Dr. Peter C. Butler, chief of endocrinology at UCLA, was tapped by Merck & Co., the maker of Januvia, to conduct a safety study on its top-selling type 2 diabetes drug. He originally declined the offer but then accepted and made his troublesome discovery.
After finding that lab rats introduced to Januvia had developed pancreatic troubles, the FDA along with the European Medicines Agency said they would develop the study further and investigate the potentially deadly link associated with the drug, according to The New York Times, which also reports that the last time the FDA acted on the work of a single researcher was in the case of another type 2 diabetes drug, Avandia. Avandia has since been severely restricted from the U.S. market and banned outright in countries covered by EMA.
Based on our previous reports, Dr. Butler’s assessment on the safety of Januvia is not the first to link the drug to possible pancreatic cancer. Previous studies have also suggested that diabetics taking Januvia also face a risk of pancreatitis (an inflammation of the pancreas) and thyroid cancer.
Januvia already carries a warning about the risk of pancreatitis, but information from the Mayo Clinic, according to our previous accounts, indicates that pancreatitis and diabetes make a person more likely to develop pancreatic cancer. Pancreatic cancer is often not diagnosed until it reaches its later stages.
The FDA announced in March through a Drug Safety Communication that pancreatic tissue taken from patients who had been on Januvia showed the kinds of cellular changes that often precede pancreatic cancer, according to our previous reports.